ELEVA CAPITAL

Art 8.

ELEVA European Selection - Class A1

30/10/2026

Monthly report

Investment objective and approach

- Aiming to achieve superior long-term risk adjusted returns
- Investing primarily in European equities and equity related securities
- Conviction investing using bottom-up stock-picking
- Flexible, opportunistic, and pragmatic approach, with no sector/country bias and style/market cap agnostic
- Using a macroeconomic overlay to support sector positioning
- Recommended investment horizon : ≥ 5 years

Key figures

Net Asset Value	272.49 €
Total Fund Assets	9,514,390,402 €

Risk Indicator / SRI

LOWER RISK — HIGHER RISK

1	2	3	**4**	5	6	7

Fund characteristics

Manager: Eric Bendahan
Legal structure: Luxembourg SICAV - UCITS
Fund launch date: 26/01/2015
Share class launch date: 09/02/2015
ISIN Code: LU1111642408
Bloomberg Ticker: EESFA1E LX
Classification: European Equity
Benchmark: STOXX Europe 600 Net Return - SXXR
Reference currency: EUR
Distribution policy: Accumulation
Valuation frequency: Daily

Administrative information

Custodian: BNP Paribas, Luxembourg branch
Fund admin: BNP Paribas, Luxembourg branch
Management company: ELEVA Capital SAS
Subscription / redemption cutoff: 12:00 Lux.
Subscription / redemption settlement: T+2

Fees

Subscription fees: Up to 3%
Redemption fees: 0%
Management fees: 1.5%
Performance fees: 15% of the outperformance to the SXXR with an underperformance compensation mechanism over 5 rolling years

Contact

Axel Plichon, Head of Business Development
axel.plichon@elevacapital.com

This document should be read in conjunction with the prospectus and relevant KIDs which are available on our website www.elevacapital.com.
Past performance is no guarantee of future results. The UCITS Fund does not benefit from any guarantee or protection, so the initial invested capital may not be fully repaid.

Performance

Sources: ELEVA Capital



Calendar year performance

	Fund	Index
2017	15.88%	10.58%
2018	-12.44%	-10.77%
2019	26.01%	26.82%
2020	2.61%	-1.99%
2021	27.60%	24.91%
2022	-11.34%	-10.64%
2023	16.54%	15.80%
2024	11.68%	8.79%
2025	19.13%	19.80%
2026	7.20%	11.66%

Cumulative performance

	Fund	Index
1 month	-0.96%	1.96%
3 months	-2.11%	-0.02%
6 months	5.01%	7.05%
9 months	3.40%	8.18%
1 year	10.39%	15.88%
3 years	59.61%	61.12%
5 years	52.19%	54.74%
Since inception	172.49%	137.52%

Monthly Comment

European markets rebounded in October, outperforming US equities thanks to their lower exposure to AI. The main driver was a sharp rotation away from the AI/Momentum complex. Renewed concerns over AI financing, with neocloud debt falling into distressed territory, and disappointing results from several US tech giants triggered a historic unwinding of Momentum strategies, as investors fled to safety into defensives. Healthcare surged 14% on strong earnings and positive trial data. Conversely, banks slumped by more than 10% as French political risk flared up again: violent riots amid the budget standoff, pushing the OAT-Bund spread to its widest level since 2011. US-Iran tensions kept oil prices elevated, with Brent climbing above $110/bbl amid attacks in the Gulf and reports of possible US strikes after the midterms. The Fed and the ECB both left rates unchanged, with the ECB adopting a slightly dovish tone. Third-quarter earnings remained supportive but did little to dampen the rotation.
In this context, ELEVA European Selection was down 0.96% vs an index up 1.96%, an underperformance of 292 bps.

Sector allocation had a slightly negative impact, affected by the underweight in consumer staples and in communication services, as well as the overweight in industrials, but somewhat compensated by the positive impact of the overweight in health care, financials and utilities. Stock picking was negative, particularly in financials and industrials.
Outperformers were exclusively defensive stocks. **UCB** was a standout performer thanks to a material guidance upgrade and a competitor's clinical setback to its drug Bimzelx. **Sandoz Group** also did well, its Investor Day highlighting significant long-term growth opportunities in biosimilars continued to resonate with investors. **Galderma** also upgraded its guidance, end markets remain unaffected by the consumption challenges.
Technology and electrification names were sold off despite delivering material guidance upgrades, as financing issues in the AI complex outweighed the positives. **ASM International** and **Prysmian** were under pressure. **Schneider Electric** also announced a poorly timed acquisition and a capital raise to fund it. Banks also were under heavy selling pressure, amid widening credit spreads and poor messaging on net interest margins with intensifying pressure on deposits. **UniCredit**, **Banco Santander**, **Erste Group Bank** and **NatWest Group** suffered in the month. Civil aerospace names (**Rolls-Royce**, **Safran**) underperformed as investors worry that high oil prices will affect aftermarket revenues.
Leading indicators are starting to turn downwards following a sustained period of improvement. Higher yields, tighter financing conditions and political uncertainties are, in our view, likely to start weighing on economic activity. For now, high nominal growth and improving productivity are supporting earnings. We note that corporates remain active in mergers and acquisitions and share buybacks.
Value and cyclicals were at 43.9% and 51.4% of the fund respectively, down materially on the previous month.

Since inception, ELEVA European Selection is up 172.49% vs an index up 137.52%, an outperformance of 3,497 bps.

ELEVA European Selection - Class A1

30/10/2026

Monthly report

Portfolio analysis

Geographic breakdown

cash excluded



Sector breakdown

cash excluded



Market capitalisation

cash excluded



Average Market Cap €124.26 bn

Risk Indicators

	Fund	Benchmark
Active Weight	66.13%	
Volatility*	16.25%	15.95%
Beta*	0.99	
Tracking Error*	4.06%	
Sharpe ratio*	0.50	0.43
Sortino Ratio*	0.62	0.53
Information Ratio*	0.31	

* since inception

Top 5 Holdings

Company	Sector	Country	Weight	ESG Score**
ASML Holding NV	Technology	Netherlands	5.13%	75
ROCHE HOLDING AG	Health Care	Switzerland	3.61%	60
AstraZeneca PLC	Health Care	United Kingdom	3.51%	69
UCB SA	Health Care	Belgium	2.95%	80
Prysmian SpA	Industrials	Italy	2.56%	72

** ELEVA proprietary score from 0 to 100

Top 3 contributors

Company	Absolute Contribution
UCB S.A.	95 bps
ROCHE HOLDING LTD	58 bps
ASTRAZENECA PLC	50 bps

Top 3 detractors

Company	Absolute Contribution
ASML HOLDING NV	-67 bps
BANCO SANTANDER, S.A.	-50 bps
SCHNEIDER ELECTRIC SE	-45 bps

Additional data

Share class	Launch date	ISIN	Bloomberg Ticker	Distribution policy	NAV
A1 (EUR) dis.	08/06/2017	LU1543705286	ELESA1D LX	Distribution	206.53
A1 (USD) acc. Hdg	09/02/2015	LU1111642580	EESFA1U LX	Accumulation	325.33

ELEVA CAPITAL

Sources: ELEVA Capital

ELEVA European Selection - Class A1

30/10/2026

Monthly report

ESG data

Investment process

Steps	nb of companies
Initial universe (financial criteria and existence of an ESG score)	784
1. Universe post Exclusions*	775
2. Portfolio post fundamental research**	51

* For more information on the exclusions applicable to the fund, please refer to the ESG Policy and the Coal Policy available on the ELEVA website

** Fundamental analysis, ESG analysis & valuation

Average ESG scores





Sources: ELEVA Capital, MSCI

Best 3 ESG ratings

Name	Sector	Country	ESG Score
SSE PLC	Utilities	United Kingdom	83
Schneider Electric SE	Industrials	France	80
UCB SA	Health Care	Belgium	80

Worst 3 ESG ratings

Name	Sector	Country	ESG Score
BP PLC	Energy	United Kingdom	41
ArcelorMittal	Materials	Luxembourg	41
Shell PLC	Energy	United Kingdom	42

ESG Performances

Growth in the number of employees



Source: ELEVA Capital

Percentage of women on the board



Source: MSCI

Signatories of the United Nations Global Compact



Source: ELEVA Capital

Carbon intensity
(in tons of CO_2 equivalent scope 1+2+3 per million € of sales)



Source: MSCI

Carbon footprint
(in tons of CO_2 equivalent scope 1+2+3 per million € invested)



Source: MSCI

Sustainable investments

Sustainable investments
(% TNA, in line with art. 2.17 SFDR)
67.25%
Source: ELEVA Capital

Taxonomy alignment
(% of Revenue, excl. sovereign)
4.88%
Source: MSCI

Coverage rate of ESG indicators

	Growth in the number of employees	% women on the board	% Signatories of the United Nations Global Compact	Carbon intensity	Carbon footprint
Fund	93%	100%	100%	100%	100%
Initial universe	87%	97%	100%	98%	98%

Legal disclaimer

This document is distributed for information purposes only and is primarily intended for subscribers of the UCI(s) presented. This is by no means a marketing document, and cannot be equated with a recommendation or investment advice. Please refer to the prospectus of the Eleva UCITS Fund and to the KID available on our website (www.elevacapital.com) before making any final investment decisions. This communication is not a recommendation or an investment advice. The sources used to carry out this reporting are considered reliable, however Eleva Capital declines all responsibility for any omission, error or inaccuracy. Eleva Capital accepts no responsibility for any direct or indirect losses caused by the use of the information provided in this document. The figures quoted relate to past years and past performance is not a reliable indicator of future performance. The STOXX Europe 600 Index is the intellectual property (including registered trademarks) of STOXX Limited, Zurich, Switzerland ("STOXX"), Deutsche Börse Group or their licensors, which is used under license. The ELEVA European Selection fund is neither sponsored nor promoted, distributed or in any other manner supported by STOXX, Deutsche Börse Group or their licensors, research partners or data providers and STOXX, Deutsche Börse Group and their licensors, research partners or data providers do not give any warranty, and exclude any liability (whether in negligence or otherwise) with respect thereto generally or specifically in relation to any errors, omissions or interruptions in the STOXX Europe 600 Index or its data. The representative and paying agent in Switzerland is Société Générale, Paris, Zurich branch, Talacker 50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the Key Information Document, the articles, and the annual and semi-annual reports are available free of charge from the representative in Switzerland.
For further details on internal ESG Ratings, please refer to the 'Regulatory Information' section of our website.

ELEVA CAPITAL